{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:10:35Z","timestamp":1784355035090,"version":"3.55.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1994,6,1]],"date-time":"1994-06-01T00:00:00Z","timestamp":770428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1994,6,1]],"date-time":"1994-06-01T00:00:00Z","timestamp":770428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[1994,6]]},"DOI":"10.1007\/bf00874436","type":"journal-article","created":{"date-parts":[[2004,12,28]],"date-time":"2004-12-28T00:25:05Z","timestamp":1104193505000},"page":"75-92","source":"Crossref","is-referenced-by-count":27,"title":["Fludarabine phosphate"],"prefix":"10.1007","volume":"12","author":[{"given":"Gladys","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BF00874436_CR1","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1021\/jm00303a605","volume":"12","author":"JA Montgomery","year":"1969","unstructured":"Montgomery JA, Hewson K: Nucleosides of 2-fluoroadenine. J Med Chem 12:498\u2013504, 1969","journal-title":"J Med Chem"},{"key":"BF00874436_CR2","first-page":"3610","volume":"40","author":"RW Brockman","year":"1980","unstructured":"Brockman RW, Cheng YC, Schabel FM Jr, Montgomery JA: Metabolism and chemotherapeutic activity of 9-\u03b2-D-arabinofuranosyl-2-fluoroadenme against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res 40:3610\u201315, 1980","journal-title":"Cancer Res"},{"issue":"5 Suppl 8","key":"BF00874436_CR3","first-page":"3","volume":"17","author":"W Plunkett","year":"1990","unstructured":"Plunkett W, Huang P, Gandhi V: Metabolism and action of fludarabine phosphate. Semin Oncol 17(5 Suppl 8):3\u201317, 1990","journal-title":"Semin Oncol"},{"key":"BF00874436_CR4","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0140-6736(72)92345-8","volume":"2","author":"ER Giblet","year":"1972","unstructured":"Giblet ER, Anderson F, Cohen B, Pollana B, Mewissen HJ: Adenosine deaminase deficiency in two patients with severely impaired immunity. Lancet 2:1067\u20138, 1972","journal-title":"Lancet"},{"key":"BF00874436_CR5","doi-asserted-by":"crossref","first-page":"826","DOI":"10.7326\/0003-4819-92-6-826","volume":"92","author":"BS Mitchell","year":"1980","unstructured":"Mitchell BS, Kelley WN: Purinogenic immunodeficiency diseases: Clinical features and molecular mechanisms. Ann Intern Med 92:826\u201332, 1980","journal-title":"Ann Intern Med"},{"key":"BF00874436_CR6","doi-asserted-by":"crossref","first-page":"733","DOI":"10.7326\/0003-4819-108-5-733","volume":"108","author":"PJ O'Dwyer","year":"1988","unstructured":"O'Dwyer PJ, Wagner B, Leyland-Jones B, Wittes RE, Cheson BD, Hoth DF: Deoxycoformycin (Pentostatin) for lymphoid malignancies. Ann Intern Med 108:733\u201343, 1988","journal-title":"Ann Intern Med"},{"key":"BF00874436_CR7","first-page":"756","volume":"1","author":"GA LePage","year":"1973","unstructured":"LePage GA, Khalig A, Gottlieb JA: Studies of 9-\u03b2-D-arabinofur-anosyladenine in man. Drug Metab Dispos 1:756\u20139, 1973","journal-title":"Drug Metab Dispos"},{"key":"BF00874436_CR8","first-page":"3911","volume":"42","author":"JA Montgomery","year":"1982","unstructured":"Montgomery JA: Has the well gone dry? The First Cain Memorial Award Lecture. Cancer Res 42:3911\u201317, 1982","journal-title":"Cancer Res"},{"key":"BF00874436_CR9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/med.2610020304","volume":"2","author":"JA Montgomery","year":"1982","unstructured":"Montgomery JA: Studies on the biologic activity of purine and pyrimidine analogs. Med Res Rev 2:271\u2013308, 1982","journal-title":"Med Res Rev"},{"key":"BF00874436_CR10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/jhet.5570160129","volume":"16","author":"JA Montgomery","year":"1979","unstructured":"Montgomery JA, Clayton SD, Shortnacy AT: An improved procedure for the preparation of 9-\u03b2-D-arabinofuranosyl-2-fluoroadenine. J Heterocyclic Chem 16:157\u201360, 1979","journal-title":"J Heterocyclic Chem"},{"key":"BF00874436_CR11","first-page":"445","volume":"67","author":"PE Noker","year":"1983","unstructured":"Noker PE, Duncan GF, El Dareer SM, Hill DL: Disposition of 9-\u03b2-D-arabinofuranosyl-2-fluoroadenine-5\u2032-phosphate in mice and dogs. Cancer Treat Rep 67:445\u201356, 1983","journal-title":"Cancer Treat Rep"},{"key":"BF00874436_CR12","first-page":"116","volume":"2","author":"L Malspeis","year":"1984","unstructured":"Malspeis L, De Souza JJV, Staubus AE, Neidhart JA, Grever MR: Pharmacokinetics of 2-F-ara-AMP in man during a phase I clinical trial. Invest New Drugs 2:116, 1984","journal-title":"Invest New Drugs"},{"key":"BF00874436_CR13","first-page":"361","volume":"25","author":"JJV De Souza","year":"1984","unstructured":"De Souza JJV, Grever M, Neidhart JA, Staubus AE, Malspeis L: Comparative pharmacokinetics and metabolism of fludarabine phosphate (NSC 312887) in man and dog. Proc Am Assoc Cancer Res 25:361, 1984.","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF00874436_CR14","first-page":"104","volume":"43","author":"FM Sirotnak","year":"1983","unstructured":"Sirotnak FM, Chello PL, Dorick DM, Montgomery JA: Specificity of systems mediating transport of adenosine, 9-\u03b2-D-arabino-furanosyl-2-fluoroadenine, and other purine nucleoside analogues in L1210 cells. Cancer Res 43:104\u20139, 1983","journal-title":"Cancer Res"},{"key":"BF00874436_CR15","first-page":"370","volume":"38","author":"YC Cheng","year":"1979","unstructured":"Cheng YC, Tsou J, Brockman RW: Enzyme activity responsible for the phosphorylation of 9-\u03b2-D-arabinofuranosyl-2-fluoroadenine (F-ara-A) to F-ara-AMP in L1210 cells. Fed Proc 38:370, 1979","journal-title":"Fed Proc"},{"key":"BF00874436_CR16","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1016\/S0021-9258(17)33354-9","volume":"251","author":"TA Krenitsky","year":"1976","unstructured":"Krenitsky TA, Tuttle JV, Koszalka GW, Chen IS, Beacham LM, Rideout JL, Elion GB: Deoxycytidine kinase from calf thymus. J Biol Chem 251:4055\u201361, 1976","journal-title":"J Biol Chem"},{"key":"BF00874436_CR17","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/0006-2952(77)90275-1","volume":"26","author":"RW Brockman","year":"1977","unstructured":"Brockman RW, Schabel FM Jr, Montgomery JA: Biologic activity of 9-\u03b2-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-\u03b2-D-arabinofuranosyladenine. Biochem Pharmacol 26:2193\u20136, 1977","journal-title":"Biochem Pharmacol"},{"key":"BF00874436_CR18","first-page":"2349","volume":"40","author":"W Plunkett","year":"1980","unstructured":"Plunkett W, Chubb S, Alexander L, Montgomery JA: Comparison of the toxicity and metabolism of 9-\u03b2-D-arabino-furanosyl-2-fluoroadenine and 9-\u03b2-D-arabino-furanosyladenine in human lymphoblastoid cells. Cancer Res 40:2349\u201355, 1980","journal-title":"Cancer Res"},{"key":"BF00874436_CR19","first-page":"2587","volume":"42","author":"VI Avramis","year":"1982","unstructured":"Avramis VI, Plunkett W: Metabolism and therapeutic efficacy of 9-\u03b2-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388. Cancer Res 42:2587\u201391, 1982","journal-title":"Cancer Res"},{"key":"BF00874436_CR20","doi-asserted-by":"crossref","first-page":"16617","DOI":"10.1016\/S0021-9258(17)46267-3","volume":"265","author":"P Huang","year":"1990","unstructured":"Huang P, Chubb S, Plunkett W: Termination of DNA synthesis by 9-\u03b2-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J Biol Chem 265:16617\u201325, 1990","journal-title":"J Biol Chem"},{"key":"BF00874436_CR21","first-page":"2260","volume":"42","author":"LE White","year":"1982","unstructured":"White LE, Shaddix SC, Brockman RW, Bennett LL Jr: Comparison of the actions of 9-\u03b2-D-arabinofuranosyl-2-fluoroadenine and 9-\u03b2-arabinofuranosyladenine on target enzymes from mouse tumor cells. Cancer Res 42:2260\u20134, 1982","journal-title":"Cancer Res"},{"key":"BF00874436_CR22","first-page":"33","volume":"22","author":"L White","year":"1981","unstructured":"White L, Shaddix SC, Cheng YC, Brockman RW, Bennett LL Jr: Inhibition of ribonucleotide reductase and DNA polymerases of tumor cells by 9-\u03b2-D-arabinofuranosyl-2-fluoroadenine-5\u2032-triphosphate (2-F-ara-ATP). Proc Am Assoc Cancer Res 22:33, 1981","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF00874436_CR23","first-page":"666","volume":"40","author":"WC Tseng","year":"1981","unstructured":"Tseng WC, Derse D, Cheng YC, Brockman RW, Bennett LL Jr: \u201cSelf-potentiation\u201d mechanism of action of 9-\u03b2-D-arabinofur-anosyl-2-fluoroadenine. Fed Proc 40:666, 1981","journal-title":"Fed Proc"},{"key":"BF00874436_CR24","first-page":"474","volume":"21","author":"WC Tseng","year":"1982","unstructured":"Tseng WC, Derse D, Cheng YC, Brockman RW, Bennett LL Jr:in vitro biological activity of 9-\u03b2-D-arabinofuranosyl-2-fluoro-adenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol Pharmacol 21:474\u20137, 1982","journal-title":"Mol Pharmacol"},{"key":"BF00874436_CR25","first-page":"19","volume":"26","author":"W Plunkett","year":"1985","unstructured":"Plunkett W, Chubb S: Toxicity, metabolism and incorporation into DNA and RNA of arabinosyl-2-fluoroadenine (F-ara-A). Proc Am Assoc Cancer Res 26:19, 1985","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF00874436_CR26","first-page":"420","volume":"31","author":"CV Catapano","year":"1990","unstructured":"Catapano CV, Chandler KB, Fernandex DJ: Effects of anticancer agents on primer RNA formation in human leukemia cells. Proc Am Assoc Cancer Res 31:420, 1990","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF00874436_CR27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/07357908909038280","volume":"7","author":"VI Avramis","year":"1989","unstructured":"Avramis VI: Pharmacodynamics and proposed mechanism of therapeutic action and host toxicity of 9-\u03b2-D-arabinofuranosyl-2-fluoroadenine monophosphate (7-araAMP) in P388 murine leukemia-bearing mice. Cancer Invest 7:129\u201337, 1989","journal-title":"Cancer Invest"},{"key":"BF00874436_CR28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0006-291X(83)90428-X","volume":"113","author":"VI Avramis","year":"1983","unstructured":"Avramis VI, Plunkett W: 2-Fluoro-ATP: A toxic metabolite of 9-\u03b2-D-arabinofuranosyl-2-fluoroadenine (F-araA). Biophys Biochem Res Comm 113:35\u201343, 1983","journal-title":"Biophys Biochem Res Comm"},{"key":"BF00874436_CR29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0006-2952(86)90521-6","volume":"35","author":"D Spriggs","year":"1986","unstructured":"Spriggs D, Robbins G, Mitchell T, Kufe D: Incorporation of 9-\u03b2-D-arabinofuranosyl-2-fluoroadenine into HL60 cellular RNA and DNA. Biochem Pharmacol 35:247\u201352, 1986","journal-title":"Biochem Pharmacol"},{"key":"BF00874436_CR30","first-page":"21","volume":"27","author":"P Huang","year":"1986","unstructured":"Huang P, Plunkett W: Preferential incorporation of arabinofur-anosyl-2-fluoroadenine (F-ara-A) into poly (A+) RNA and its inhibitory effects on transcription and translation. Proc Am Assoc Cancer Res 27:21, 1986","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF00874436_CR31","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1016\/0006-2952(81)90535-9","volume":"30","author":"MC Huang","year":"1981","unstructured":"Huang MC, Hatfield K, Roetker AW, Montgomery JA, Blakley RL: Analogs of 2\u2032-deoxyadenosine: Facile enzymatic preparation and growth inhibitory effects on human cell lines. Biochem Pharmacol 30:2663\u201371, 1981","journal-title":"Biochem Pharmacol"},{"key":"BF00874436_CR32","series-title":"New Series. Volume 4","first-page":"261","volume-title":"Rational Basis for Chemotherapy","author":"VL Verhoef","year":"1983","unstructured":"Verhoef VL, Fridland A: Differential sensitivity of human T- and B-lymphoblasts to cytotoxic nucleoside analogues. In: Chabner Bruce A (ed) Rational Basis for Chemotherapy. (UCLA Symposium on Molecular and Cellular Biology. New Series. Volume 4.) Alan R. Liss, Inc., New York, 1983, pp 261\u201373"},{"key":"BF00874436_CR33","first-page":"4661","volume":"44","author":"DH Boldt","year":"1984","unstructured":"Boldt DH, Von Hoff DD, Kuhn JG, Hersh M: Effects on human peripheral lymphocytes ofin-vivo administration of 9-\u03b2-D-arabinofuranosyl-2-fluoroadenine-5\u2032-monophosphate (NSC-312887), a new purine antimetabolite. Cancer Res 44:4661\u20136, 1984","journal-title":"Cancer Res"},{"key":"BF00874436_CR34","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/0277-5379(88)90103-4","volume":"24","author":"B Lathan","year":"1988","unstructured":"Lathan B, Diehl V, Clark GM, Von Hoff DD: Cytotoxic activity of 9-\u03b2-D-arabinofuranosyl-2-fluoroadenine 5-monophosphate (fludarabine, NSC-312887) in a human tumor cloning system. Eur J Cancer Clin Oncol 24:1891\u20135, 1988","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"Suppl 8","key":"BF00874436_CR35","first-page":"39","volume":"17","author":"MR Grever","year":"1990","unstructured":"Grever MR, Leiby J, Kraut E, Metz E, Neidhart J, Balcerzak S, Malspeis L: A comprehensive phase I and II clinical investigation of fludarabine phosphate. Semin Oncol 17 (Suppl 8):39\u201348, 1990","journal-title":"Semin Oncol"},{"key":"BF00874436_CR36","first-page":"4183","volume":"44","author":"JJ Hutton","year":"1984","unstructured":"Hutton JJ, Von Hoff DD, Kuhn J, Phillips J, Hersh M, Clark G: Phase I clinical investigation of 9-\u03b2-D-arabinofuranosyl-2-fluoroadenine 5-monophosphate (NSC 312887), a new purineantimetabolite. Cancer Res 44:4183\u20136, 1984","journal-title":"Cancer Res"},{"key":"BF00874436_CR37","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/BF00263892","volume":"15","author":"ES Casper","year":"1985","unstructured":"Casper ES, Mittleman A, Kelson D, Young CW: Phase I clinical trial of fludarabine phosphate (F-ara-AMP). Cancer Chemother Pharmacol 15:233\u20135, 1985","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF00874436_CR38","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/0277-5379(85)90283-4","volume":"21","author":"JJ Kavanagh","year":"1985","unstructured":"Kavanagh JJ, Krakoff IH, Bodey GP: Phase I study of fludarabine (2-fluoro-ara-AMO). Eur J Cancer Clin Oncol 21:1009\u201311, 1985","journal-title":"Eur J Cancer Clin Oncol"},{"key":"BF00874436_CR39","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/jnci\/80.6.447","volume":"80","author":"JM Leiby","year":"1988","unstructured":"Leiby JM, Grever MR, Staubus AE, Neidhart JA, Malspeis L: Phase I clinical investigation of fludarabine phosphate by a loading dose and continuous-infusion schedule. J Natl Cancer Inst 80:447\u20139, 1988","journal-title":"J Natl Cancer Inst"},{"key":"BF00874436_CR40","first-page":"165A","volume":"64","author":"MR Grever","year":"1984","unstructured":"Grever MR, Leiby JM, Kraut EH, Neidhart JA, Malspeis L, Balcerzak SP: A phase I investigation of 2-fluoro-araAMP in refractory leukemia. Blood 64:165A, 1984","journal-title":"Blood"},{"key":"BF00874436_CR41","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.1986.4.1.74","volume":"4","author":"RP Warrell Jr","year":"1986","unstructured":"Warrell RP Jr, Berman E: Phase I and II study of fludarabine phosphate in leukemia: Therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 4:74\u20139, 1986","journal-title":"J Clin Oncol"},{"key":"BF00874436_CR42","first-page":"5953","volume":"46","author":"DR Spriggs","year":"1986","unstructured":"Spriggs DR, Stopa E, Mayer RJ, Schoene W, Kufe DW: Fludarabine phosphate (NSC 312887) infusions for the treatment of acute leukemia: Phase I and neuropathological study. Cancer Res 46:5953\u20138, 1986","journal-title":"Cancer Res"},{"key":"BF00874436_CR43","first-page":"7226","volume":"50","author":"VI Avramis","year":"1990","unstructured":"Avramis VI, Champagne J, Sato J, Krailo M, Ettinger LJ, Poplack DG, Finkelstein J, Reaman G, Hammond GD, Holcenberg JS: Pharmacology of fludarabine phosphate after a phase I\/II trial by a loading bolus and continuous infusion in pediatrie patients. Cancer Res 50:7226\u201331, 1990","journal-title":"Cancer Res"},{"key":"BF00874436_CR44","first-page":"A359","volume":"10","author":"VI Avramis","year":"1991","unstructured":"Avramis VI, Wierzma S, Holcenberg JS, Reaman G, Hammond D, Sato J: Clinical pharmacology of fludarabine phosphate (F-ara-AMP) followed by cytosine arabinoside in pediatrie patients with relapsed leukemia. (Abstract) Proc Annu Meet Am Soc Clin Oncol 10:A359, 1991","journal-title":"(Abstract) Proc Annu Meet Am Soc Clin Oncol"},{"key":"BF00874436_CR45","first-page":"A1266","volume":"33","author":"JK Sato","year":"1992","unstructured":"Sato JK, Wiersma S, Krailo M, Bostrom B, Shurin S, Cheerva A, Hammond D, Avramis V: Phase I clinical and pharmacodynamic study of continuous infusion (CI) fludarabine followed by CI cytosine arabinoside (ara-C) in relapsed leukemia. (Abstract) Proc annu Meet Am Assoc Cancer Res 33:A1266, 1992","journal-title":"(Abstract) Proc annu Meet Am Assoc Cancer Res"},{"key":"BF00874436_CR46","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF00256699","volume":"17","author":"MR Hersch","year":"1986","unstructured":"Hersch MR, Kuhn JG, Phillips JL, Clark G, Ludden TM, Von Hoff DD: Pharmacokinetic study of fludarabine phosphate (NSC 312887). Cancer Chemother Pharmacol 17:277\u201380, 1986","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF00874436_CR47","first-page":"358","volume":"26","author":"JJV DeSouza","year":"1985","unstructured":"DeSouza JJV, Leiby JM, Staubus AE, Grever MR, Malspeis L: Altered pharmacokinetics of fludarabine phosphate (F) by 2\u2032-deoxycoformycin (DCF) in the dog and analysis of a route of fludarabine activation. Proc Am Assoc Cancer Res 26:358, 1985","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF00874436_CR48","first-page":"1313","volume":"71","author":"GB Weiss","year":"1987","unstructured":"Weiss GB, Metch B, Von Hoff DD, Taylor SA, Saiers JH: Phase II trial of fludarabine phosphate in patients with head and neck cancer: A Southwest Oncology Group study. Cancer Treat Rep 71:1313\u201314, 1987","journal-title":"Cancer Treat Rep"},{"key":"BF00874436_CR49","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1007\/BF00171986","volume":"8","author":"A Mittelman","year":"1990","unstructured":"Mittelman A, Savona S, Puccio C, Chun H, Ahmed T, Feldman E, Sullivan P, Arnold P, Arlin Z: Phase II trial of fludarabine phosphate (F-Ara-AMP) in patients with advanced head and neck cancer. Invest New Drugs 8:S65\u20137, 1990","journal-title":"Invest New Drugs"},{"key":"BF00874436_CR50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF00175089","volume":"9","author":"SA Taylor","year":"1991","unstructured":"Taylor SA, Crowley J, Vogel FS, Townsend JJ, Eyre HJ, Jaeckle KA, Hynes HE, Guy JT: Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors. A Southwest Oncology Group trial. Invest New Drugs 9:195\u20137, 1991","journal-title":"Invest New Drugs"},{"key":"BF00874436_CR51","first-page":"71","volume":"6","author":"SA Taylor","year":"1987","unstructured":"Taylor SA, Eyre HJ: Randomized phase II trials of acivicin (AT-125, NSC 163501) and fludarabine (2-fluoro-ara-AMP, NSC 312887) (2FLAMP) in recurrent malignant gliomas: A SWOG study. Proc Am Assoc Clin Oncol 6:71, 1987","journal-title":"Proc Am Assoc Clin Oncol"},{"key":"BF00874436_CR52","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/00000421-198810000-00015","volume":"11","author":"TL Cascino","year":"1988","unstructured":"Cascino TL, Brown LD, Morton RF, Everson LK, Marschke RF, Dinapoli RP, O'Fallon JR: Evaluation of fludarabine phosphate in patients with recurrent glioma. Am J Clin Oncol 11:586\u20138, 1988","journal-title":"Am J Clin Oncol"},{"key":"BF00874436_CR53","first-page":"1235","volume":"70","author":"JT Carpenter Jr","year":"1986","unstructured":"Carpenter JT Jr, Vogel CL, Wang G, Raney M: Phase II evaluation of fludarabine in patients with metastatic breast cancer: A Southeastern Cancer Study Group trial. Cancer Treat Rep 70:1235\u20136, 1986","journal-title":"Cancer Treat Rep"},{"key":"BF00874436_CR54","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF00254183","volume":"22","author":"A Mittelman","year":"1988","unstructured":"Mittelman A, Ashikari R, Ahmed T, Savona S, Arnold P, Arlin Z: Phase II trial of fludarabine phosphate (F-araAMP) in patients with advanced breast cancer. Cancer Chemother Pharmacol 22:63\u20134, 1988","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF00874436_CR55","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF00170780","volume":"6","author":"JA Ajani","year":"1988","unstructured":"Ajani JA, Abbruzzese JL, Faintuch JS, Blackburn R, Levin B, Bowman BM: Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma. Invest New Drugs 6:47\u201350, 1988","journal-title":"Invest New Drugs"},{"key":"BF00874436_CR56","first-page":"1319","volume":"71","author":"WH Harvey","year":"1987","unstructured":"Harvey WH, Fleming TR, Von Hoff DD, Katterhagen JG, Coltman CA Jr: Phase II study of fludarabine phosphate in previously untreated patients with colorectal carcinoma. A Southwest Oncology Group study. Cancer Treat Rep 71:1319\u201320, 1987","journal-title":"Cancer Treat Rep"},{"key":"BF00874436_CR57","first-page":"1111","volume":"71","author":"WH Harvey","year":"1987","unstructured":"Harvey WH, Fleming TR, Beltran G, Saiers JH, Oishi N, Von Hoff DD: Phase II study of fludarabine phosphate in previously untreated patients with hepatoma: A South-west Oncology Group study. Cancer Treat Rep 71:1111\u201312, 1987","journal-title":"Cancer Treat Rep"},{"key":"BF00874436_CR58","first-page":"1123","volume":"70","author":"GR Weiss","year":"1986","unstructured":"Weiss GR, Crowley J, Von Hoff DD, Taylor SA, Belt RJ, Coltman CA Jr, Hynes HE, Costanzi JJ: Phase II study of fludarabine phosphate for the treatment of advanced non-small cell carcinoma of the lung: A Southwest Oncology Group study. Cancer Treat Rep 70:1123\u20134, 1986","journal-title":"Cancer Treat Rep"},{"key":"BF00874436_CR59","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00170779","volume":"6","author":"JM Rainey","year":"1988","unstructured":"Rainey JM, Hill JB, Crowley J: Evaluation of fludarabine in small cell carcinoma: A Southwest Oncology Group study. Invest New Drugs 6:45\u20136, 1988","journal-title":"Invest New Drugs"},{"key":"BF00874436_CR60","first-page":"425","volume":"70","author":"JJ Kavanagh","year":"1986","unstructured":"Kavanagh JJ, Stringer CA, Copeland LJ, Gershenson DM, Saul P: Phase II trial of fludarabine in patients with epithelial ovarian cancer. Cancer Treat Rep 70:425\u20136, 1986","journal-title":"Cancer Treat Rep"},{"key":"BF00874436_CR61","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/00000421-198804000-00011","volume":"11","author":"DD Von Hoff","year":"1988","unstructured":"Von Hoff DD, Kronmal R, O'Toole RV, Surwit EA, Hutton JJ, Alberts DS: Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced ovarian cancer: A Southwest Oncology Group study. Am J Clin Oncol 11:146\u20138, 1988","journal-title":"Am J Clin Oncol"},{"key":"BF00874436_CR62","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00000421-199106000-00004","volume":"14","author":"DD Von Hoff","year":"1991","unstructured":"Von Hoff DD, Green S, Alberts DS, Stock-Novack DL, Surwit EA, Miller TP, Stephens RL: Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced endometrial cancer. A Southwest Oncology Group study. Am J Clin Oncol 14:193\u20134, 1991","journal-title":"Am J Clin Oncol"},{"key":"BF00874436_CR63","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/00000421-199010000-00014","volume":"13","author":"DD Von Hoff","year":"1990","unstructured":"Von Hoff DD, Green S, Surwit EA, Hannigan EV, Alberts DS: Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced cervical cancer. A Southwest Oncology Group study. Am J Clin Oncol 13:433\u20135, 1990","journal-title":"Am J Clin Oncol"},{"key":"BF00874436_CR64","first-page":"103","volume":"7","author":"L Kilton","year":"1988","unstructured":"Kilton L, Benson A, Greenburg A, Johnson P, Shapiro C, Shiomoto G, Blough R, Weidner L: Phase II trial of fludarabine phosphate (FAMP) in adenocarcinoma of the pancreas: An Illinois Cancer Council study. Proc Am Soc Clin Oncol 7:103, 1988","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF00874436_CR65","first-page":"543","volume":"71","author":"L Balducci","year":"1987","unstructured":"Balducci L, Blumenstein B, Von Hoff DD, Davis M, Hynes HE, Bukowsky RM, Crawford ED: Evaluation of fludarabine phosphate in renal cell carcinoma: A South-west Oncology Group study. Cancer Treat Rep 71:543\u20134, 1987","journal-title":"Cancer Treat Rep"},{"key":"BF00874436_CR66","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF00170869","volume":"7","author":"DH Shevrin","year":"1989","unstructured":"Shevrin DH, Lad TE, Kilton LJ, Cobleigh MA, Vogelzang NJ, Blough RR, Weidner LL: Phase II trial of fludarabine phosphate in advanced renal cell cancer: An Illinois Cancer Council study. Invest New Drugs 7:251\u20133, 1989","journal-title":"Invest New Drugs"},{"key":"BF00874436_CR67","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00000421-198708000-00017","volume":"10","author":"R Pazdur","year":"1987","unstructured":"Pazdur R, Samson MK, Baker LH: Fludarabine phosphate: Phase II evaluation in advanced soft-tissue sarcomas. Am J Clin Oncol 10:341\u20133, 1987","journal-title":"Am J Clin Oncol"},{"key":"BF00874436_CR68","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00194559","volume":"9","author":"JA Kish","year":"1991","unstructured":"Kish JA, Kopecky K, Samson MK, Von Hoff DD, Fletcher WS, Kempf RA, Muggia FM: Evaluation of fludarabine phosphate in malignant melanoma. A South-west Oncology Group study. Invest New Drugs 9:105\u20138, 1991","journal-title":"Invest New Drugs"},{"key":"BF00874436_CR69","first-page":"2719","volume":"47","author":"JM Leiby","year":"1987","unstructured":"Leiby JM, Snider KM, Kraut EH, Metz EN, Malpeis L, Grever MR: Phase II trial of 9-\u03b2-D-arabinofuranosyl-2-fluoroadenine 5\u2032-monophosphate in non-Hodgkin's lymphoma: Prospective comparison of response with deoxycytidine kinase activity. Cancer Res 47:2719\u201322, 1987","journal-title":"Cancer Res"},{"key":"BF00874436_CR70","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.1992.10.5.790","volume":"10","author":"J Redman","year":"1992","unstructured":"Redman J, Cabanillas F, Velazquez W, McLaughlin P, Hagemeister F, Swan F, Rodriguez M, Plunkett W, Keating M: Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low grade lymphoma. J Clin Oncol 10:790\u20134, 1992","journal-title":"J Clin Oncol"},{"key":"BF00874436_CR71","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/bjc.1991.253","volume":"64","author":"JS Whelan","year":"1991","unstructured":"Whelan JS, Davis CL, Rule S, Ranson M, Smith OP, Mehta AV, Catovsky D, Rohatiner AZS, Lister TA: Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br J Cancer 64:120\u20133, 1991","journal-title":"Br J Cancer"},{"issue":"Suppl 8","key":"BF00874436_CR72","first-page":"63","volume":"17","author":"H Hochster","year":"1990","unstructured":"Hochster H, Cassileth P: Fludarabine phosphate therapy of non-Hodgkin's lymphoma. Semin Oncol 17 (Suppl 8):63\u20135, 1990","journal-title":"Semin Oncol"},{"key":"BF00874436_CR73","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/jnci\/82.16.1353","volume":"82","author":"DD Von Hoff","year":"1990","unstructured":"Von Hoff DD, Dahlberg S, Hartstock RJ, Eyre HJ: Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: A Southwest Oncology Group study. J Natl Cancer Inst 82:1353\u20135, 1990","journal-title":"J Natl Cancer Inst"},{"key":"BF00874436_CR74","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF00177259","volume":"8","author":"EH Kraut","year":"1990","unstructured":"Kraut EH, Crowley JJ, Grever MR, Keppen MD, Bonnet JD, Hynes HE, Salmon SE: Phase II study of fludarabine phosphate in multiple myeloma. Invest New Drugs 8:199\u2013200, 1990","journal-title":"Invest New Drugs"},{"key":"BF00874436_CR75","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V75.10.1928.1928","volume":"75","author":"HM Kantarjian","year":"1990","unstructured":"Kantarjian HM, Alexanian R, Koller CA, Kurzrock R, Keating MJ: Fludarabine therapy in macroglobulinemic lymphoma. Blood 75:1928\u201331, 1990","journal-title":"Blood"},{"key":"BF00874436_CR76","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0002-9343(93)90231-D","volume":"95","author":"MA Dimopoulos","year":"1993","unstructured":"Dimopoulos MA, O'Brien Susan, Kantarjian H, Pierce S, DeLasalle K, Barlogie B, Alexanian R, Keating MJ: Fludarabine therapy in Waldenstr<ouml>m's macroglobulinemia. Am J Med 95:49\u201352, 1993","journal-title":"Am J Med"},{"key":"BF00874436_CR77","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/1097-0142(19910301)67:5<1291::AID-CNCR2820670503>3.0.CO;2-Y","volume":"67","author":"HM Kantarjian","year":"1991","unstructured":"Kantarjian HM, Schachner J, Keating MJ: Fludarabine therapy in hairy cell leukemia. Cancer 67:1291\u20133, 1991","journal-title":"Cancer"},{"key":"BF00874436_CR78","first-page":"223a","volume":"68","author":"MR Grever","year":"1986","unstructured":"Grever MR, Coltman CA Jr, Files JC, Greenberg BR, Hutton JJ, Talley RL, Von Hoff DD, Balcerzak SP: Fludarabine monophosphate in chronic lymphocytic leukemia. Blood 68:223a, 1986","journal-title":"Blood"},{"key":"BF00874436_CR79","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood.V74.1.19.19","volume":"74","author":"MJ Keating","year":"1989","unstructured":"Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, Velasquez W, Plunkett W, Freireich EJ, McCredie KB: Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 74:19\u201325, 1989","journal-title":"Blood"},{"key":"BF00874436_CR80","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/ajh.2830290307","volume":"29","author":"BD Cheson","year":"1988","unstructured":"Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ, Foon KA: Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-Sponsored Working Group. Am J Hematol 29:152\u201363, 1988","journal-title":"Am J Hematol"},{"key":"BF00874436_CR81","first-page":"250a","volume":"72","author":"A Mittelman","year":"1988","unstructured":"Mittelman A, Lichtman S, Budman D, Silver R, Savona S, Chun H, Puccio C, Ahmed T, Arnold P, Arlin Z: Therapy of chronic lymphocytic leukemia (CLL) with fludarabine phosphate (FAMP). Blood 72:250a, 1988","journal-title":"Blood"},{"key":"BF00874436_CR82","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.1991.9.9.1562","volume":"9","author":"CA Puccio","year":"1991","unstructured":"Puccio CA, Mittelman A, Lichtman SM, Silver RT, Budman DR, Ahmed T, Feldman EJ, Coleman M, Arnold PM, Arlin ZA, Chun HG: A loading dose\/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. J Clin Oncol 9:1562\u20139, 1991","journal-title":"J Clin Oncol"},{"key":"BF00874436_CR83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01714952","volume":"63","author":"W Hiddemann","year":"1991","unstructured":"Hiddemann W, Rottmann R, Vormann B, Thiel A, Essink M, Ottensmeier C, Freund M, Buchner T, van de Loo J: Treatment of advanced chronic lymphocytic leukemia by fludarabine: Results of a clinical phase-II study. Ann Hematol 63:1\u20134, 1991","journal-title":"Ann Hematol"},{"key":"BF00874436_CR84","first-page":"207a","volume":"72","author":"MJ Keating","year":"1988","unstructured":"Keating MJ, Kantarjian H, Talpaz M, Koller C, Redman J, McCredie KB: Fludarabine \u2014 Results of therapy in previously treated (PT) and untreated (UNT) chronic lymphocytic leukemia (CLL). Blood 72:207a, 1988","journal-title":"Blood"},{"key":"BF00874436_CR85","doi-asserted-by":"crossref","first-page":"159a","DOI":"10.1182\/blood.V74.1.19.19","volume":"74","author":"MJ Keating","year":"1989","unstructured":"Keating MJ, O'Brien S, Kantarjian H, Koller C, Freireich EJ, McCredie KB: High response rate with fludarabine \u00b1 prednisone in untreated chronic lymphocytic leukemia. Blood 74:159a, 1989","journal-title":"Blood"},{"key":"BF00874436_CR86","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0002-9343(91)80164-H","volume":"90","author":"HM Kantarjian","year":"1991","unstructured":"Kantarjian HM, Childs C, O'Brien S, Huh Y, Miloslav B, Schachner J, Koller C, Keating MJ: Efficacy of flud-\u2192abine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia. Am J Med 90:223\u20138, 1991","journal-title":"Am J Med"},{"key":"BF00874436_CR87","first-page":"55","volume":"93","author":"JG Buchanan","year":"1981","unstructured":"Buchanan JG: Treatment of chronic lymphocytic leukemia. N Engl J Med 93:55\u20138, 1981","journal-title":"N Engl J Med"},{"key":"BF00874436_CR88","unstructured":"Foon KA, Gale RP: Chronic lymphocytic leukemia. In: Gale RP (ed) Leukemia Therapy. Boston, 1986, pp 165\u201380"},{"key":"BF00874436_CR89","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/ajh.2830320115","volume":"32","author":"BD Cheson","year":"1989","unstructured":"Cheson BD: Current approaches to the chemotherapy of B-cell chronic lymphocytic leukemia: A review. Am J Hematol 32:72\u20137, 1989","journal-title":"Am J Hematol"},{"key":"BF00874436_CR90","first-page":"1225","volume":"70","author":"HG Chun","year":"1986","unstructured":"Chun HG, Leyland-Jones BR, Caryk SM, Hoth DF: Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep 70:1225\u20138, 1986","journal-title":"Cancer Treat Rep"},{"key":"BF00874436_CR91","first-page":"1449","volume":"70","author":"DE Merkel","year":"1986","unstructured":"Merkel DE, Griffen NL, Kagan-Hallet K, Von Hoff DD: Central nervous system toxicity with fludarabine. Cancer Treat Rep 70:1449\u201350, 1986","journal-title":"Cancer Treat Rep"},{"key":"BF00874436_CR92","doi-asserted-by":"crossref","first-page":"114","DOI":"10.7326\/0003-4819-118-2-199301150-00007","volume":"118","author":"RB Cohen","year":"1993","unstructured":"Cohen RB, Abdallah JM, Gray JR, Foss F: Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann Intern Med 118:114\u2013116, 1993","journal-title":"Ann Intern Med"},{"key":"BF00874436_CR93","first-page":"343","volume-title":"Physiological and Regulatory Functions of Adenosine and Adenine Nucleotides","author":"JW Phillis","year":"1979","unstructured":"Phillis JW, Kostopoulus GK, Edstrom JP, Ellis SW: Role of adenosine and adenine nucleotides in central nervous function. In: Baer HP, Drummond GI (eds) Physiological and Regulatory Functions of Adenosine and Adenine Nucleotides. New York, Raven Press, 1979, pp 343\u201359"},{"key":"BF00874436_CR94","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1471-4159.1973.tb07549.x","volume":"21","author":"I Havlica","year":"1973","unstructured":"Havlica I, Ababei L, Branisteanu D, Topoliceanu F: Preliminary data on the possible hypnogenic role of adenosine. Neurochemistry 21:1019\u201320, 1973","journal-title":"Neurochemistry"},{"key":"BF00874436_CR95","first-page":"299","volume":"696","author":"FF Snyder","year":"1982","unstructured":"Snyder FF, Lukey T: Kinetic considerations for the regulation of adenosine and deoxyadenosine metabolism in mouse and human tissues based on a thymocyte model. Biochem Biophys Acta 696:299\u2013307, 1982","journal-title":"Biochem Biophys Acta"},{"key":"BF00874436_CR96","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF00203548","volume":"5","author":"PG Hurst","year":"1987","unstructured":"Hurst PG, Haviv MD, Garewal H, Bluestein M, Paquin M, Greenberg BR: Pulmonary toxicity associated with fludarabine phosphate. Invest New Drugs 5:207\u201310, 1987","journal-title":"Invest New Drugs"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00874436.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF00874436\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00874436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00874436.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T04:32:43Z","timestamp":1682915563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF00874436"}},"subtitle":["A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma"],"short-title":[],"issued":{"date-parts":[[1994,6]]},"references-count":96,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1994,6]]}},"alternative-id":["BF00874436"],"URL":"https:\/\/doi.org\/10.1007\/bf00874436","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,6]]}}}